HLA-C and neuroblastoma: To overcome this challenge, the researchers employed immunopeptidomics, a technique that allowed them to discover and identify TSAs from eight neuroblastoma cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models, showing a wide range of MHC expression.